Cardiol Therapeutics closes $17.25 million bought deal offering including full exercise of over-allotment option

1 minute read
04 June 2020
Client work

On June 4, 2020, Cardiol Therapeutics Inc. (TSX: CRDL) announced the closing of its previously announced bought deal short form prospectus offering of units for aggregate gross proceeds of $17,250,000 which includes the full exercise of the over-allotment option.

The offering was completed by a syndicate of underwriters led by Canaccord Genuity Corp. and included Raymond James Ltd., AltaCorp Capital Inc., and Echelon Wealth Partners Inc.

Cardiol is a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol products for heart diseases.

Gowling WLG advised Cardiol with respect to this offering with a team that included Brett Kagetsu, Tara Amiri-Khaledi, Jill Dunn, Raymond Ong, Jason Mullins and Sarah Baddeley (corporate finance) and Brent Kerr and Anita Yuk (tax), with the assistance of paralegal Toni Vodola.

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.
Related   Capital Markets, Banking & Finance, Tax, Cannabis

Related Insights & Resources

View all insights Related Insights & Resources
Articles
13 July 2021 Canada Emergency Wage Subsidy: TPM-17 and transfer pricing considerations
Articles
13 July 2021 Canada's APA program: An overview
Client work
07 July 2021 Silverline acquires award-winning Salesforce partner Shift CRM

Team

Download or print PDF